TABLE OF CONTENTS
|
16 December 2011 |
 |  |  |
 | News Analysis Research Highlights Research & Reviews
Careers | |
Nature Reviews Drug Discovery is on Twitter |  |
 |
Advertisement |
 |
Scientific Reports – Call for papers Publishing made easy! Entirely open access with papers accepted on technical merit, the community evaluates the importance of papers post-peer review. Scientific Reports exists to facilitate the rapid peer review and publication of research that is of interest to specialists within any given field in the natural sciences.
Submit now! | |
 |
|
News | Top |
 |
 |
 |
Class of once-weekly diabetes drugs poised for approval doi:10.1038/nm1211-1528b A decision is expected from the US Food and Drug Administration by 28 January on the regulatory approval of the once-weekly injectable diabetes medication, Bydureon, made by Amylin Pharmaceuticals and Eli Lilly. Full Text |
 |
 |
 |
Interest groups jostle to influence PDUFA V doi:10.1038/nbt1211-1062 The contents of the finalized package of formal recommendations for the Prescription Drug User Fee Act V reflect many rounds of negotiations involving the US Food and Drug Administration, industry, medical groups, patient and consumer representatives and the general public. Full Text |
 |
 |
 |
Industry continues dabbling with open innovation models doi:10.1038/nbt1211-1063a Several open innovation initiatives have been launched in a bid to share intellectual property and thereby speed up drug discovery. Full Text |
 |
 |
 |
Four-in-one HIV pill may be exception among combination drugs doi:10.1038/nm1211-1528a If approved, Gilead’s four-in-one HIV 'Quad' pill promises the same virus-controlling ability as the four drugs separately but should be easier to use for people with the infection. Full Text |
 |
Analysis | Top |
 |
 |
 |
Big MAC attack in osteoarthritis doi:10.1038/scibx.2011.1311 An international team has shown that inhibiting the complement system could help slow disease progression in osteoarthritis, thus handing a potentially disease-modifying strategy to companies developing complement 5 inhibitors. Full Text |
 |
 |
 |
Crizotinib doi:10.1038/nrd3600 In August 2011, crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test. Full Text |
 |
 |
 |
Personalized medicine in oncology: next generation doi:10.1038/nrd3603 This article outlines the challenges, such as clinical trial design, biomarker selection, accurately forecasting sales potential and pricing, that face pharmaceutical companies in the development of targeted drugs. Full Text |
 |
Research Highlights | Top |
 |
 |
 |
Analgesia: Unravelling epigenetic mechanisms of chronic pain doi:10.1038/nrd3606 Results from a new study suggest that histone deacetylase inhibitors could be used as analgesics to target the development of chronic pain. Full Text |
 |
 |
 |
Medical devices: A protective stent coating doi:10.1038/nrd3604 Researchers have shown that coating stents with cathelicidin, an antimicrobial peptide released from neutrophils, could represent a novel strategy for preventing restenosis. Full Text |
 |
 |
 |
Therapeutics: Another tool in the BCR–ABL kit? doi:10.1038/nrc3173 Inhibiting an interaction between the SH2 and kinase domains of BCR–ABL, which facilitates kinase activation, prevents leukaemogenesis in mice and can restore sensitivity to tyrosine kinase inhibitors. Full Text |
 |
Research & Reviews | Top |
 |
 |
 |
|
 |
No comments:
Post a Comment